We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Kalorama Estimates Orphan Drug Market Will Expand 11.5% Annually Through 2017
News

Kalorama Estimates Orphan Drug Market Will Expand 11.5% Annually Through 2017

Kalorama Estimates Orphan Drug Market Will Expand 11.5% Annually Through 2017
News

Kalorama Estimates Orphan Drug Market Will Expand 11.5% Annually Through 2017

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Kalorama Estimates Orphan Drug Market Will Expand 11.5% Annually Through 2017"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The world orphan drug market reached $61 billion in 2012, according to Kalorama Information's research. Incentives have created a thriving market, and the increasing incidence of diseases affecting the elderly will drive the market to expand at a rate of 11.5% annually through 2017. Learn about the latest developments and opportunities in this important market in their detailed report:
"The World Market for Orphan Drugs (Markets for Oncology, Hematology, Neurology, Endocrine, Metabolic and Other Drugs)".

In recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases, which are eligible for development incentives. In the U.S., a drug may be designated an orphan drug if the disease or condition for which it is indicated affects less than 200,000 Americans. Pharmaceutical companies have seen an opportunity in developing these orphan drugs with reduced regulatory costs and incentivized development.

This comprehensive report looks at market trends and provides in-depth market data for the U.S., along with estimates for the market opportunity in Europe, Japan and globally. With over 400 pages of market analysis and over 120 figures and tables, the report provides in-depth coverage of key competitors and important trends and challenges for makers of orphan drug treatments.

The following segments are discussed:
Oncology
Hematology
Musculoskeletal
Neurology
Endocrine
Metabolic
Others
Analysis of the "Pure" Orphan Drug Market:

The world orphan drug market is difficult to determine due to variances in orphan drug status and requirements by country. Some publicized estimates of orphan drug markets include brand revenue that is not truly related to the orphan status of the drug. In The World Market for Orphan Drugs, Kalorama Information separates strictly orphan revenue from total brand revenue where necessary to provide a true picture of the pure orphan drug market opportunity.

Demographics, Costs, Regulation and Other Trends Examined:

The list of trends and factors affecting the orphan drug market remain lengthy. It is affected both by trends that affect the pharmaceutical industry as a whole and trends that specifically affect the orphan drug market:
Orphan drug pricing
Aging of the population
Increasing life expectancy
Trends in birth rates
Cost effectiveness
Regulatory environments
Orphan drug incentives
Population demographics
Product availability by country/region
Extensive Company Coverage:

The World Market for Orphan Drugs looks extensively at what major pharmaceutical companies and smaller concerns are doing within this drug category and profiles over 45 companies. Company market share for both the US and global markets is provided. A variety of companies with both designations and designation/approvals are discussed.

Advertisement